More on RotaShield and intussusception: the role of age at the time of vaccination
- PMID: 16088803
- DOI: 10.1086/431512
More on RotaShield and intussusception: the role of age at the time of vaccination
Abstract
Background: RotaShield, a vaccine intended to prevent severe rotavirus diarrhea, was withdrawn in July 1999, 9 months after it became available in the United States, because of a temporal association with intussusception events that occurred in vaccinated infants. We explore here the effect of age on the risk of intussusception.
Methods: We reanalyzed a case-control database of the Centers for Disease Control and Prevention by use of a 21-day window, to define vaccine-associated events. We obtained data on vaccine use from the National Immunization Survey and estimated the age-stratified background incidence of intussusception by use of Healthcare Cost and Utilization Project data. We combined these data to estimate how absolute risk varies with age and to model the projected population-attributable risk associated with 3 different vaccination schedules.
Results: We found that the incidence of intussusception associated with the first dose of vaccine increased with age. Infants > or = 90 days old accounted for 80% of cases of intussusception associated with a first dose but had received only 38% of first doses. Modeling of the recommended schedule of vaccination at ages 2, 4, and 6 months projected 1 intussusception event/11,000-16,000 vaccine recipients; modeling of a 2-dose schedule beginning in the neonatal period projected 1 intussusception event/38,000-59,000 vaccine recipients.
Conclusions: The practice of initiating immunization after age 90 days, which we call "catch-up" vaccination, contributed disproportionately to the occurrence of intussusception associated with the use of RotaShield. A fully implemented 2-dose vaccination schedule begun during the neonatal period would lead to, at most, a 7% increase in the incidence of intussusception above the annual background incidence.
Comment in
-
Age dependence of the relation between reassortant rotavirus vaccine (RotaShield) and intussusception.J Infect Dis. 2006 Mar 15;193(6):898; author reply 898-9. doi: 10.1086/500217. J Infect Dis. 2006. PMID: 16479526 No abstract available.
-
Is there a safe age for vaccinating infants with tetravalent rhesus-human reassortant rotavirus vaccine?J Infect Dis. 2006 Dec 15;194(12):1793-4; author reply 1794-5. doi: 10.1086/509264. J Infect Dis. 2006. PMID: 17109356 No abstract available.
Similar articles
-
Rotavirus vaccination and intussusception: can we decrease temporally associated background cases of intussusception by restricting the vaccination schedule?Pediatrics. 2006 Aug;118(2):e258-64. doi: 10.1542/peds.2005-2874. Pediatrics. 2006. PMID: 16882770
-
Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007.Pediatrics. 2008 Jun;121(6):1206-12. doi: 10.1542/peds.2007-3793. Pediatrics. 2008. PMID: 18519491
-
Postmarketing monitoring of intussusception after RotaTeq vaccination--United States, February 1, 2006-February 15, 2007.MMWR Morb Mortal Wkly Rep. 2007 Mar 16;56(10):218-22. MMWR Morb Mortal Wkly Rep. 2007. PMID: 17363890
-
Rotavirus live, oral, pentavalent vaccine.Clin Ther. 2007 Dec;29(12):2724-37. doi: 10.1016/j.clinthera.2007.12.018. Clin Ther. 2007. PMID: 18201590 Review.
-
A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception.J Infect Dis. 2005 Sep 1;192 Suppl 1:S22-9. doi: 10.1086/431510. J Infect Dis. 2005. PMID: 16088801 Review.
Cited by
-
Leveraging Beneficial Off-Target Effects of Live-Attenuated Rotavirus Vaccines.Vaccines (Basel). 2022 Mar 10;10(3):418. doi: 10.3390/vaccines10030418. Vaccines (Basel). 2022. PMID: 35335050 Free PMC article. Review.
-
Vaccines for preventing rotavirus diarrhoea: vaccines in use.Cochrane Database Syst Rev. 2021 Nov 17;11(11):CD008521. doi: 10.1002/14651858.CD008521.pub6. Cochrane Database Syst Rev. 2021. PMID: 34788488 Free PMC article. Review.
-
Novel vaccine safety issues and areas that would benefit from further research.BMJ Glob Health. 2021 May;6(Suppl 2):e003814. doi: 10.1136/bmjgh-2020-003814. BMJ Glob Health. 2021. PMID: 34011502 Free PMC article. Review.
-
The Rotavirus Vaccine Landscape, an Update.Pathogens. 2021 Apr 26;10(5):520. doi: 10.3390/pathogens10050520. Pathogens. 2021. PMID: 33925924 Free PMC article. Review.
-
Cord Blood-Based Approach to Assess Candidate Vaccine Adjuvants Designed for Neonates and Infants.Vaccines (Basel). 2021 Jan 27;9(2):95. doi: 10.3390/vaccines9020095. Vaccines (Basel). 2021. PMID: 33514054 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
